Opinion|Videos|June 12, 2024
Final Insights on Current Bladder Cancer Clinical Trials
Author(s)Neal Shore, MD
Neal Shore, MD, FACS, shares his final thoughts on the current landscape of clinical trials for both non-muscle-invasive bladder cancer and muscle-invasive bladder cancer, providing insights into the potential impact and future directions of these studies.
Advertisement
Episodes in this series
Video content above is prompted by the following question(s):
- Based on the data presented, how might these novel therapeutic approaches potentially change the standard of care and clinical management of NMIBC and MIBC in the future?
Advertisement
Related to this article
Hepatitis B functional cure with bepirovirsen held in 90% to 92% of responders 48 weeks after stopping all therapy, per data at The Liver Meeting 2026.
GOLD leaders say COPD is diagnosed too late and its smoking-only image is outdated, and the 2027 report puts rehab and non-drug care up front.
Most patients with CLL/SLL who discontinued a first-line BTK inhibitor did not start second-line therapy, and older age was linked to worse outcomes.
Resmetirom real-world data at The Liver Meeting 2026 show 12-month gains in liver stiffness, fat, and enzymes among patients with MASH in 3 US data sets.
A study of 132 patients with AML given venetoclax-based therapy, 10 profiled by single-cell sequencing, linked immune features to treatment response.
This week in health equity and access: Medicaid cuts; mailed FIT outreach; EEOC pregnancy rules; GLP-1 Bridge access; and 2027 policy shifts.
Greater 340B activity—measured by county-level hospital child sites and contract pharmacy arrangements—was associated with significantly higher county-level total and out-of-pocket health care spending.
Clinicians at Population Health Roundtables shared obesity care innovations, from pharmacist-led models to same-day liver screening
Advertisement
Advertisement
Trending on AJMC
1
EEOC Reportedly Plans to Narrow Pregnancy Accommodation Rules
2
How the GOLD 2026 Guidelines Updated COPD Diagnosis and Treatment
3
CF, Bronchiectasis Antimicrobial Resistance Varies Widely by Region
4
Medicaid Cuts and Caregiving in Congress: Andy Kim
5